Wall Street analyst estimates for 10x Genomics, Inc. (TXG): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Headquartered in Pleasanton, California, 10x Genomics, Inc. (founded in 2012 and known as 10X Technologies, Inc. until November 2014) is a prominent life science technology company. The firm specializes in creating and distributing sophisticated instrumentation, essential consumables, and software designed for in-depth analysis of biological systems. Its market presence extends globally, covering North America, Europe, the Middle East, Africa, China, and the Asia Pacific.
Analyst Consensus
| Strong Buy | 0 |
| Buy | 10 |
| Hold | 11 |
| Sell | 1 |
| Strong Sell | 0 |
| Total analysts | 22 |
| Avg rating (1-5) | 0.41 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-05 | $-0.26 | ||
| 2026-08-06 | $-0.14 | $-0.24 | +42.4% |
| 2026-05-07 | $-0.10 | $-0.29 | +65.5% |
| 2026-02-12 | $-0.13 | $-0.19 | +31.6% |
| 2025-11-06 | $-0.22 | $-0.07 | -214.3% |
| 2025-08-07 | $0.28 | $-0.35 | +180.0% |
| 2025-05-08 | $-0.36 | $-0.45 | +20.0% |
| 2025-02-12 | $-0.40 | $-0.29 | -37.9% |
Valuation Ratios
| Price / Book | 15.39 |
| EV / EBITDA | 427.97 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $71.1M | $146.3M | $245.9M | $298.8M | $490.5M | $516.4M | $618.7M | $610.8M | $642.8M |
| Cost of Revenue | $10.6M | $28.7M | $61.0M | $58.5M | $74.1M | $120.4M | $209.4M | $196.3M | $198.9M |
| Gross Profit | $60.5M | $117.7M | $184.9M | $240.4M | $416.4M | $396.0M | $409.3M | $414.5M | $443.9M |
| Research & Development | $32.2M | $47.5M | $83.1M | $123.4M | $211.8M | $265.7M | $270.3M | $264.7M | $238.6M |
| Selling, General & Admin | $46.7M | $87.9M | $130.8M | $202.3M | $257.6M | $298.3M | $343.3M | $344.3M | $316.1M |
| Operating Expenses | $78.9M | $135.5M | $213.9M | $325.7M | $469.3M | $564.0M | $674.6M | $609.0M | $554.8M |
| Operating Income | -$18.4M | -$110.8M | -$29.1M | -$85.3M | -$52.9M | -$167.9M | -$265.3M | -$194.6M | -$110.9M |
| EBITDA | -$13.6M | -$106.1M | -$20.9M | -$513.8M | -$24.6M | -$128.5M | -$205.1M | -$134.0M | $3.9M |
| Interest Expense | $811,000 | $2.4M | $3.1M | $1.7M | $866,000 | $476,000 | $33,000 | $4,000 | 0 |
| Pre-tax Income | -$18.7M | -$112.4M | -$31.0M | -$534.5M | -$53.7M | -$162.0M | -$248.8M | -$177.7M | -$39.9M |
| Income Tax | $21,000 | $87,000 | $218,000 | $8.3M | $4.5M | $4.0M | $6.3M | $4.9M | $3.6M |
| Net Income | -$18.8M | -$112.5M | -$31.3M | -$542.7M | -$58.2M | -$166.0M | -$255.1M | -$182.6M | -$43.5M |
| EPS | $-1.62 | $-8.40 | $-0.80 | $-5.37 | $-0.53 | $-1.46 | $-2.18 | $-1.52 | $-0.35 |
| EPS (Diluted) | $-1.62 | $-8.40 | $-0.80 | $-5.37 | $-0.53 | $-1.46 | $-2.18 | $-1.52 | $-0.35 |
| Shares Outstanding (Diluted) | $11.6M | $13.4M | $39.1M | $101.2M | $110.3M | $113.9M | $117.2M | $120.5M | $124.7M |
Price
| Price | $90.04 |
| Market Cap | $11.4B |
| Exchange | NASDAQ |
| Country | US |
Related companies: CERT · GRDN · JANX · NUVB · OMCL · OMDA · PGNY
Explore sector: Healthcare · Biotechnology
More sections of TXG: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Investment Academy — learn to analyze stocks